Associate Professor, Medicine, Medical College of Wisconsin
Hematology
Dr. Kenneth J. Friedman, MD
|
|
Give Review
Kenneth Friedman practices Hematology. He attended State University of New York Upstate Medical University. He has 2 awards "CMS Meaningful Use Stage 1 Certification" and "Super Doctor". Kenneth Friedman is a published physician as well. He has 50 publications published. The latest was: A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, respo...
Publications
- A critical appraisal of one-stage and chromogenic assays of factor VIII activity.
- Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.
- Comparison of several von Willebrand factor (VWF) activity assays for monitoring patients undergoing treatment with VWF/FVIII concentrates: improved performance with a...
- Crucial role for the VWF A1 domain in binding to type IV collagen.
- An optimized fluorogenic ADAMTS13 assay with increased sensitivity for the investigation of patients with thrombotic thrombocytopenic purpura.
- No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation.
- Collagen Binding Provides a Sensitive Screen for Variant von Willebrand Disease.
- Use of purified fibrinogen concentrate for dysfibrinogenemia and importance of laboratory fibrinogen activity measurement.
- Comparison of Type I, Type III, and Type VI Collagen Binding Assays in Diagnosis of VWD.
- Factor VIII/von Willebrand factor concentrate therapy for ventricular assist device-associated acquired von Willebrand disease.
- Von Willebrand factor mutations and new sequence variations identified in healthy controls are more frequent in the African-American population.
- Von Willebrand disease in the United States: a perspective from wisconsin.
- Hematocrit and C-reactive protein predict treatment response times in ADAMTS13-deficient thrombotic microangiopathy.
- Therapeutic consequences for misdiagnosis of Type 2N von Willebrand disease.
- Gain-of-function GPIb ELISA assay for VWF activity in the Zimmerman Program for the Molecular and Clinical Biology of VWD.
- Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.
- Value of ADAMTS13 activity and inhibitor in the postmortem diagnosis of thrombotic thrombocytopenic purpura.
- Elevated procalcitonin and C-reactive protein as potential biomarkers of sepsis in a subpopulation of thrombotic microangiopathy patients.
- Type 2B von Willebrand disease associated with the release of platelet agglutinates from megakaryocytes in the bone marrow.
- Comparison and stability of ADAMTS13 activity in therapeutic plasma products.
- Genetic mutations in von Willebrand disease identified by DHPLC and DNA sequence analysis.
- The pathogenicity of von Willebrand factor in thrombotic thrombocytopenic purpura: reconsideration of treatment with cryopoor plasma.
- A prothrombotic phenotype in the Copenhagen rat strain.
- Anti-GPVI-associated ITP: an acquired platelet disorder caused by autoantibody-mediated clearance of the GPVI/FcRgamma-chain complex from the human platelet surface.
- Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity.
- Human parvovirus B19 infection presenting as persistent anemia in renal transplant recipients.
- An annotated bibliography on autologous transfusion.
- A phase III trial of recombinant human erythropoietin therapy in nonanemic orthopedic patients subjected to aggressive removal of blood for autologous use: dose, respo...
- Protein C deficiency. A cause of unusual or unexplained thrombosis.
- Allelic distribution of the glycoprotein Ia (alpha2-integrin) C807T/G873A dimorphisms among caucasian venous thrombosis patients and six racial groups.
- Heparin cofactor activity and antithrombin III antigen levels in preeclampsia.
- Multisite study for genotyping of the factor II (prothrombin) G20210A mutation by the invader assay.
- Acquired Glanzmann's thrombasthenia as part of multiple-autoantibody syndrome in a pediatric heart transplant patient.
- Genotyping of factor V G1691A (Leiden) without the use of PCR by invasive cleavage of oligonucleotide probes.
- On improving the cost-effectiveness of autologous blood transfusion practices.
- Measurement of von Willebrand factor cleaving protease (ADAMTS-13): results of an international collaborative study involving 11 methods testing the same set of coded ...
- Laboratory diagnosis of von Willebrand disease: results from a prospective and blind study in 32 laboratories worldwide using lyophilized plasmas.
- Contribution of the glycoprotein Ia 807TT, methylene tetrahydrofolate reductase 677TT and prothrombin 20210GA genotypes to prothrombotic risk among factor V 1691GA (Le...
- Enzymatic amplification of specific cDNA inserts from lambda gt11 libraries.
- Urgent reversal of warfarin with prothrombin complex concentrate.
- An amino acid polymorphism within the RGD binding domain of platelet membrane glycoprotein IIIa is responsible for the formation of the Pena/Penb alloantigen system.
- Prevalence of prothrombin G20210A, factor V G1691A (Leiden), and methylenetetrahydrofolate reductase (MTHFR) C677T in seven different populations determined by multipl...
- The pharmacokinetic diversity of two von Willebrand factor (VWF)/ factor VIII (FVIII) concentrates in subjects with congenital von Willebrand disease. Results from a p...
- Absent collagen binding in a VWF A3 domain mutant: utility of the VWF:CB in diagnosis of VWD.
- Abnormal binding of factor VIII is linked with the substitution of glutamine for arginine 91 in von Willebrand factor in a variant form of von Willebrand disease.
- Limitations of the ristocetin cofactor assay in measurement of von Willebrand factor function.
- Severe deficiency of VWF-cleaving protease (ADAMTS13) activity defines a distinct population of thrombotic microangiopathy patients.
- Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6°C storage.
- Lepirudin prevents lethal effects of Shiga toxin in a canine model.
Schools
Suny Downstate Medical Center
Mt Sinai Hospital
Flw Duke University
Johns Hopkins Hospital
Doctors Specialties
- Dermatopathology
- Hematology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Super Doctor
Education
-
New York Presbyterian Hospital - Columbia Campus -
Temple University Hospital -
State University of New York Upstate Medical University
Hospital
-
Froedtert Memorial Lutheran Hospital
Helpful Reviews
Similar Doctors
|
|
Dr. Purnima Sau, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael C. Goodman, MD |
|
|
Dr. Aizenhawar J. Marrogi, MD |
|
|
Dr. Chin-Yung Chang, MD |
|
|
Dr. William K. Kelly, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick A. Cross, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patricia C. Brown, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Gurdeep Chhabra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kashif Firozvi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Marcia L. Will, MD |
|
|
Dr. Barbara E. McAlpine, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeff D. Harvell, MD |
|
|
Dr. Nicola S. Bravo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Carmen M. Williams, MD |